Takeda's Dengue Vaccine Is Effective in Late-Stage Study
- Vaccine is effective in preventing insect-borne dengue fever
- Drugmaker is advancing with efforts to support shot’s launch
This article is for subscribers only.
Takeda Pharmaceutical Co.’s experimental dengue vaccine hit its main goal in a late-stage study, showing it’s effective in preventing the mosquito-borne virus that afflicts roughly 400 million people a year.
The vaccine prevented all four strains of dengue virus from causing the potentially lethal illness, also known as break-bone fever, the Japanese drugmaker said in a statement Tuesday. While studies so far haven’t raised significant safety concerns, a review of the data will continue, Takeda said.